Free Trial

Exact Sciences (EXAS) Competitors

Exact Sciences logo
$64.64 -0.21 (-0.32%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$64.55 -0.09 (-0.14%)
As of 10/24/2025 07:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

EXAS vs. BIIB, UTHR, INCY, NBIX, IONS, EXEL, BMRN, MDGL, RGEN, and HALO

Should you be buying Exact Sciences stock or one of its competitors? The main competitors of Exact Sciences include Biogen (BIIB), United Therapeutics (UTHR), Incyte (INCY), Neurocrine Biosciences (NBIX), Ionis Pharmaceuticals (IONS), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Madrigal Pharmaceuticals (MDGL), Repligen (RGEN), and Halozyme Therapeutics (HALO). These companies are all part of the "biotechnology" industry.

Exact Sciences vs. Its Competitors

Exact Sciences (NASDAQ:EXAS) and Biogen (NASDAQ:BIIB) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, dividends, analyst recommendations, risk, earnings and institutional ownership.

Exact Sciences has a beta of 1.24, suggesting that its share price is 24% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.13, suggesting that its share price is 87% less volatile than the S&P 500.

In the previous week, Biogen had 28 more articles in the media than Exact Sciences. MarketBeat recorded 44 mentions for Biogen and 16 mentions for Exact Sciences. Biogen's average media sentiment score of 1.04 beat Exact Sciences' score of 0.94 indicating that Biogen is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Exact Sciences
8 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Biogen
21 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
1 Very Negative mention(s)
Positive

Biogen has a net margin of 15.31% compared to Exact Sciences' net margin of -34.19%. Biogen's return on equity of 13.85% beat Exact Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Exact Sciences-34.19% -1.75% -0.76%
Biogen 15.31%13.85%8.32%

88.8% of Exact Sciences shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 1.2% of Exact Sciences shares are held by insiders. Comparatively, 0.2% of Biogen shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Biogen has higher revenue and earnings than Exact Sciences. Exact Sciences is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Exact Sciences$2.94B4.16-$1.03B-$5.43-11.90
Biogen$10.00B2.20$1.63B$10.4614.33

Exact Sciences currently has a consensus price target of $69.90, suggesting a potential upside of 8.14%. Biogen has a consensus price target of $180.69, suggesting a potential upside of 20.55%. Given Biogen's higher probable upside, analysts clearly believe Biogen is more favorable than Exact Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Exact Sciences
1 Sell rating(s)
2 Hold rating(s)
19 Buy rating(s)
2 Strong Buy rating(s)
2.92
Biogen
0 Sell rating(s)
20 Hold rating(s)
11 Buy rating(s)
0 Strong Buy rating(s)
2.35

Summary

Biogen beats Exact Sciences on 10 of the 17 factors compared between the two stocks.

Get Exact Sciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for EXAS and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EXAS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

EXAS vs. The Competition

MetricExact SciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$12.28B$3.43B$6.24B$10.69B
Dividend YieldN/A2.27%5.72%4.82%
P/E Ratio-11.9027.2231.2830.77
Price / Sales4.16462.81563.45174.94
Price / Cash11.5246.1437.0861.44
Price / Book4.9810.4012.056.61
Net Income-$1.03B-$52.83M$3.33B$277.10M
7 Day Performance5.57%2.10%1.93%2.56%
1 Month Performance20.42%12.33%7.77%3.77%
1 Year Performance-6.47%14.14%56.40%33.01%

Exact Sciences Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
EXAS
Exact Sciences
4.4353 of 5 stars
$64.64
-0.3%
$69.90
+8.1%
-8.0%$12.28B$2.94B-11.907,000Analyst Forecast
BIIB
Biogen
4.7276 of 5 stars
$146.63
+2.5%
$180.69
+23.2%
-18.5%$20.97B$9.68B14.027,605Trending News
Upcoming Earnings
Analyst Upgrade
Analyst Revision
UTHR
United Therapeutics
4.846 of 5 stars
$432.69
-0.1%
$457.21
+5.7%
+19.5%$19.55B$2.88B16.891,305Positive News
Upcoming Earnings
Analyst Forecast
Insider Trade
INCY
Incyte
4.4895 of 5 stars
$86.17
-1.6%
$84.79
-1.6%
+39.9%$17.10B$4.24B19.582,617Upcoming Earnings
Analyst Forecast
NBIX
Neurocrine Biosciences
4.3215 of 5 stars
$141.33
+0.9%
$163.72
+15.8%
+24.7%$13.89B$2.36B41.811,800Upcoming Earnings
Analyst Forecast
IONS
Ionis Pharmaceuticals
3.4728 of 5 stars
$73.55
+0.6%
$78.50
+6.7%
+82.8%$11.65B$705M-39.971,069Analyst Forecast
EXEL
Exelixis
4.7584 of 5 stars
$34.54
-12.0%
$44.42
+28.6%
+37.7%$10.57B$2.17B16.611,147Analyst Upgrade
Analyst Revision
Gap Down
High Trading Volume
BMRN
BioMarin Pharmaceutical
4.9836 of 5 stars
$53.07
-0.4%
$93.26
+75.7%
-22.6%$10.23B$2.85B15.753,040News Coverage
Positive News
Upcoming Earnings
Analyst Forecast
Analyst Revision
MDGL
Madrigal Pharmaceuticals
4.824 of 5 stars
$439.97
+0.2%
$532.70
+21.1%
+107.6%$9.75B$180.13M-34.2490Positive News
Analyst Forecast
RGEN
Repligen
4.1864 of 5 stars
$154.54
+1.3%
$169.62
+9.8%
+23.0%$8.58B$634.44M-618.141,778Analyst Forecast
HALO
Halozyme Therapeutics
4.8524 of 5 stars
$66.47
-0.8%
$72.89
+9.7%
+34.2%$7.84B$1.02B15.21390Analyst Forecast

Related Companies and Tools


This page (NASDAQ:EXAS) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners